|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DSTN |
Gene summary for DSTN |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DSTN | Gene ID | 11034 |
| Gene name | destrin, actin depolymerizing factor | |
| Gene Alias | ACTDP | |
| Cytomap | 20p12.1 | |
| Gene Type | protein-coding | GO ID | GO:0006928 | UniProtAcc | P60981 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 11034 | DSTN | GSM4909285 | Human | Breast | IDC | 8.49e-25 | -2.95e-01 | 0.21 |
| 11034 | DSTN | GSM4909286 | Human | Breast | IDC | 2.62e-33 | -3.06e-01 | 0.1081 |
| 11034 | DSTN | GSM4909287 | Human | Breast | IDC | 1.29e-17 | -4.87e-01 | 0.2057 |
| 11034 | DSTN | GSM4909288 | Human | Breast | IDC | 1.11e-02 | -1.55e-01 | 0.0988 |
| 11034 | DSTN | GSM4909292 | Human | Breast | IDC | 1.05e-06 | 3.80e-01 | 0.1236 |
| 11034 | DSTN | GSM4909293 | Human | Breast | IDC | 2.22e-04 | -8.48e-02 | 0.1581 |
| 11034 | DSTN | GSM4909294 | Human | Breast | IDC | 4.61e-21 | 1.39e-01 | 0.2022 |
| 11034 | DSTN | GSM4909296 | Human | Breast | IDC | 2.55e-12 | -2.64e-01 | 0.1524 |
| 11034 | DSTN | GSM4909297 | Human | Breast | IDC | 2.40e-31 | -4.82e-01 | 0.1517 |
| 11034 | DSTN | GSM4909298 | Human | Breast | IDC | 2.09e-02 | 2.17e-01 | 0.1551 |
| 11034 | DSTN | GSM4909302 | Human | Breast | IDC | 2.19e-04 | -2.35e-01 | 0.1545 |
| 11034 | DSTN | GSM4909303 | Human | Breast | IDC | 5.32e-04 | 2.64e-01 | 0.0438 |
| 11034 | DSTN | GSM4909304 | Human | Breast | IDC | 2.27e-36 | -4.93e-01 | 0.1636 |
| 11034 | DSTN | GSM4909309 | Human | Breast | IDC | 2.35e-14 | -4.54e-01 | 0.0483 |
| 11034 | DSTN | GSM4909311 | Human | Breast | IDC | 8.64e-50 | -1.64e-01 | 0.1534 |
| 11034 | DSTN | GSM4909312 | Human | Breast | IDC | 5.46e-10 | 1.61e-01 | 0.1552 |
| 11034 | DSTN | GSM4909315 | Human | Breast | IDC | 4.35e-71 | 4.92e-01 | 0.21 |
| 11034 | DSTN | GSM4909316 | Human | Breast | IDC | 7.75e-32 | 4.13e-01 | 0.21 |
| 11034 | DSTN | GSM4909317 | Human | Breast | IDC | 9.12e-38 | 4.51e-01 | 0.1355 |
| 11034 | DSTN | GSM4909318 | Human | Breast | IDC | 2.33e-39 | 7.16e-01 | 0.2031 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:003297029 | Skin | cSCC | regulation of actin filament-based process | 142/4864 | 397/18723 | 8.50e-06 | 1.13e-04 | 142 |
| GO:1902905112 | Skin | cSCC | positive regulation of supramolecular fiber organization | 83/4864 | 209/18723 | 8.87e-06 | 1.17e-04 | 83 |
| GO:0110053111 | Skin | cSCC | regulation of actin filament organization | 103/4864 | 278/18723 | 2.78e-05 | 3.12e-04 | 103 |
| GO:003295629 | Skin | cSCC | regulation of actin cytoskeleton organization | 127/4864 | 358/18723 | 3.83e-05 | 4.13e-04 | 127 |
| GO:0051495110 | Skin | cSCC | positive regulation of cytoskeleton organization | 86/4864 | 226/18723 | 4.08e-05 | 4.34e-04 | 86 |
| GO:0008154110 | Skin | cSCC | actin polymerization or depolymerization | 81/4864 | 218/18723 | 1.70e-04 | 1.47e-03 | 81 |
| GO:0032535111 | Skin | cSCC | regulation of cellular component size | 131/4864 | 383/18723 | 1.89e-04 | 1.59e-03 | 131 |
| GO:0008064110 | Skin | cSCC | regulation of actin polymerization or depolymerization | 71/4864 | 188/18723 | 2.38e-04 | 1.95e-03 | 71 |
| GO:0030832110 | Skin | cSCC | regulation of actin filament length | 71/4864 | 189/18723 | 2.86e-04 | 2.28e-03 | 71 |
| GO:004362411 | Skin | cSCC | cellular protein complex disassembly | 49/4864 | 136/18723 | 6.00e-03 | 2.95e-02 | 49 |
| GO:003004212 | Skin | cSCC | actin filament depolymerization | 24/4864 | 59/18723 | 9.59e-03 | 4.30e-02 | 24 |
| GO:003297030 | Thyroid | HT | regulation of actin filament-based process | 49/1272 | 397/18723 | 3.65e-05 | 7.57e-04 | 49 |
| GO:190290330 | Thyroid | HT | regulation of supramolecular fiber organization | 47/1272 | 383/18723 | 6.02e-05 | 1.13e-03 | 47 |
| GO:003295630 | Thyroid | HT | regulation of actin cytoskeleton organization | 43/1272 | 358/18723 | 1.97e-04 | 2.87e-03 | 43 |
| GO:000701530 | Thyroid | HT | actin filament organization | 50/1272 | 442/18723 | 2.71e-04 | 3.73e-03 | 50 |
| GO:002241123 | Thyroid | HT | cellular component disassembly | 47/1272 | 443/18723 | 1.60e-03 | 1.48e-02 | 47 |
| GO:190290528 | Thyroid | HT | positive regulation of supramolecular fiber organization | 26/1272 | 209/18723 | 2.06e-03 | 1.82e-02 | 26 |
| GO:003298419 | Thyroid | HT | protein-containing complex disassembly | 27/1272 | 224/18723 | 2.69e-03 | 2.24e-02 | 27 |
| GO:003253525 | Thyroid | HT | regulation of cellular component size | 40/1272 | 383/18723 | 4.50e-03 | 3.22e-02 | 40 |
| GO:011005329 | Thyroid | HT | regulation of actin filament organization | 30/1272 | 278/18723 | 8.17e-03 | 4.76e-02 | 30 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DSTN | deletion | Frame_Shift_Del | novel | c.249delN | p.Leu84CysfsTer16 | p.L84Cfs*16 | P60981 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| DSTN | SNV | Missense_Mutation | c.385C>G | p.Gln129Glu | p.Q129E | P60981 | protein_coding | tolerated(0.19) | benign(0.001) | TCGA-EK-A2RJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| DSTN | SNV | Missense_Mutation | c.404G>T | p.Cys135Phe | p.C135F | P60981 | protein_coding | tolerated(0.08) | benign(0.001) | TCGA-EK-A2RJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| DSTN | SNV | Missense_Mutation | novel | c.272C>T | p.Thr91Ile | p.T91I | P60981 | protein_coding | deleterious(0.01) | probably_damaging(0.976) | TCGA-AA-A01P-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
| DSTN | SNV | Missense_Mutation | c.349N>C | p.Tyr117His | p.Y117H | P60981 | protein_coding | deleterious(0) | possibly_damaging(0.822) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| DSTN | SNV | Missense_Mutation | rs138670114 | c.61C>T | p.Arg21Cys | p.R21C | P60981 | protein_coding | tolerated(0.2) | benign(0.02) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| DSTN | insertion | Frame_Shift_Ins | rs767965259 | c.300_301insT | p.Leu103PhefsTer12 | p.L103Ffs*12 | P60981 | protein_coding | TCGA-AA-3492-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| DSTN | deletion | Frame_Shift_Del | rs750962255 | c.301delN | p.Leu103CysfsTer6 | p.L103Cfs*6 | P60981 | protein_coding | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | ||
| DSTN | insertion | Frame_Shift_Ins | rs767965259 | c.308dupT | p.Leu103PhefsTer12 | p.L103Ffs*12 | P60981 | protein_coding | TCGA-DM-A1HA-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | ||
| DSTN | insertion | Frame_Shift_Ins | rs767965259 | c.300_301insT | p.Leu103PhefsTer12 | p.L103Ffs*12 | P60981 | protein_coding | TCGA-G4-6309-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | xeloda | PD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |